Journal Watch · Journal of Medicinal Chemistry · 2026

Structure-Based Discovery of (<i>E</i>)- and (<i>Z</i>)-4-Oxobut-2-enoate Derivatives as Novel Covalent Pin1 Inhibitors with Antitumor Activity.

Altogether, 4-oxobut-2-enoate derivatives were disclosed as new templates for further developing potent covalent Pin1 inhibitors.

Tian M, Chen Y, Zhou J et al.Journal of Medicinal Chemistry3 min readPharma relevance 50/100

DOI: 10.1021/acs.jmedchem.6c00041PMID: 42388100Study type: research study

TL;DR

Altogether, 4-oxobut-2-enoate derivatives were disclosed as new templates for further developing potent covalent Pin1 inhibitors.

Key findings

  • Altogether, 4-oxobut-2-enoate derivatives were disclosed as new templates for further developing potent covalent Pin1 inhibitors.

What they did

The binding kinetic investigations revealed that both (<i>E</i>)- and (<i>Z</i>)-4-oxobut-2-enoate warheads exhibited an appropriate electrophilic activity (<i>k</i><sub>inact</sub> = 0.006-3.60 min<sup>-1</sup>), conferring them as favorable covalent warheads for developing potent Pin1 inhibitors. The SAR investigations resulted in four (<i>Z</i>)-isomers (<b>T29</b>, <b>T39-T41</b>: enzymatic IC<sub>50</sub> = 0.02-0.08 μM) with excellent enzymatic activity, while the (<i>E</i>)-isomer <b>T7</b> (enzymatic IC<sub>50</sub> = 1.54 μM) was found to potently suppress the proliferation of MDA-MB-468 cancer cells by downregulating the Pin1 substrates c-Myc and Cyclin D1.

Full abstract (original)

Background: Peptidyl-prolyl <i>cis</i>-<i>trans</i> isomerase Pin1 is a promising anticancer target that is overexpressed in numerous cancers and associated with poor prognosis. Herein, two series of covalent Pin1 inhibitors featuring an (<i>E</i>)- or a (<i>Z</i>)-4-oxobut-2-enoate moiety as the electrophilic warhead were discovered, and their binding features were revealed by six cocrystal structures.

What they did: The binding kinetic investigations revealed that both (<i>E</i>)- and (<i>Z</i>)-4-oxobut-2-enoate warheads exhibited an appropriate electrophilic activity (<i>k</i><sub>inact</sub> = 0.006-3.60 min<sup>-1</sup>), conferring them as favorable covalent warheads for developing potent Pin1 inhibitors. The SAR investigations resulted in four (<i>Z</i>)-isomers (<b>T29</b>, <b>T39-T41</b>: enzymatic IC<sub>50</sub> = 0.02-0.08 μM) with excellent enzymatic activity, while the (<i>E</i>)-isomer <b>T7</b> (enzymatic IC<sub>50</sub> = 1.54 μM) was found to potently suppress the proliferation of MDA-MB-468 cancer cells by downregulating the Pin1 substrates c-Myc and Cyclin D1.

Results & conclusions: Altogether, 4-oxobut-2-enoate derivatives were disclosed as new templates for further developing potent covalent Pin1 inhibitors.

Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.6c00041 · PubMed 42388100.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Medicinal Chemistry study find?

Altogether, 4-oxobut-2-enoate derivatives were disclosed as new templates for further developing potent covalent Pin1 inhibitors.

What type of study is this?

It is a research study, published in Journal of Medicinal Chemistry in 2026. The binding kinetic investigations revealed that both (<i>E</i>)- and (<i>Z</i>)-4-oxobut-2-enoate warheads exhibited an appropriate electrophilic activity (<i>k</i><sub>inact</sub> = 0.006-3.60 min<sup>-1</sup>), conferring them as favorable covalent warheads for developing potent Pin1 inhibitors.

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acs.jmedchem.6c00041. PubMed ID: 42388100. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Tian M, Chen Y, Zhou J et al.. Structure-Based Discovery of (&lt;i&gt;E&lt;/i&gt;)- and (&lt;i&gt;Z&lt;/i&gt;)-4-Oxobut-2-enoate Derivatives as Novel Covalent Pin1 Inhibitors with Antitumor Activity.. Journal of Medicinal Chemistry (2026). DOI: 10.1021/acs.jmedchem.6c00041.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/structure-based-discovery-of-lt-i-gt-e-lt-i-gt-and-lt-i-gt-z-lt-i-gt-4-o-c00041/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides